An update from OKYO Pharma Limited Sponsored ADR ( (OKYO) ) is now available.
On March 10, 2025, OKYO Pharma Limited announced the filing of an application for Fast Track designation with the U.S. FDA for urcosimod, aimed at treating neuropathic corneal pain, a severe condition without any FDA-approved treatment. This move marks a significant milestone in the company’s efforts to address the unmet needs of patients suffering from this debilitating condition, potentially enhancing OKYO Pharma’s position in the biopharmaceutical industry.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain and dry eye disease. The company is listed on the NASDAQ Capital Market and is dedicated to discovering and developing novel molecules to address these ocular conditions.
YTD Price Performance: 26.55%
Average Trading Volume: 165,198
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $48.46M
For an in-depth examination of OKYO stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com